CLINICAL ROLE -
Prostate Cancer Drug Granted Breakthrough Therapy Designation
Lynparza is a first in class PARP inhibitor for the monotherapy treatment of patients with metastatic castration resistant prostate cancer.
Read More
Venetoclax Granted Breakthrough Designation for Acute Myeloid Leukemia
Venetoclax is an inhibitor of the B-cell lymphoma-2 protein used in combination with hypomethylating agents in treatment-naive AML patients.
Lymphoma Treatment Market Poised for Massive Growth
Adcetris is currently the only approved molecular-targeted therapy for Hodgkins lymphoma.
NFL Legend Battles Back from Prostate Cancer
NFL Hall of Famer and Super Bowl champion Mike Haynes seeks to spread awareness about prostate cancer following his fight with the disease.
Understanding Gene Expression May Improve Hepatitis B Treatment
Researchers seek to predict age-related responses to hepatitis B vaccination.
New Process Helps Find Cancerous Cells During Surgery
Handheld miniature microscope allows surgeons to see cancer at a cellular level.
High-Deductible Health Care Enrollees Not More Likely to Seek Cheaper Prices
Study finds decreased spending is not due to enrollees switching to lower cost providers.
Increased Health Insurance Coverage Needed for Patients with Mental Illness
Study finds passage of Affordable Care Act caused a spike in ER visits for young adults with mental illnesses and circulatory system disease.
Second-Line Metastatic Pancreatic Cancer Treatment Shows Promise
Abraxane and gemcitabine evaluated in first-line patients with metastatic pancreatic cancer.
CMS: Medicaid Prescription Drug Reforms Could Save Billions
Centers for Medicare and Medicaid Services issues final ruling that seeks to rein in the growing cost of prescription drugs.
Genetic Markers May Predict Melanoma Survival
Inherited genetic markers in immune response pathways associated with melanoma survival.
Early ART Can Restore Immune Systems of HIV-Positive Infants
ART treatment results in higher CD4+ T-cell frequency, lower cellular activation, and higher proportions of naive T-cells.
FDA Approves Expanded Indication for Metastatic Melanoma Combination
The expanded use of Opdivo and Yervoy includes patients with BRAF V600 wild-type mutation-positive unresectable or metastatic melanoma.
Fatal Drug Trial Not Impacted by Cannabinoids
Researchers stress that no conclusions can be drawn yet about the safety of cannabis and cannabinoid research.
Near-Infrared Light Drug Delivery Method May Enhance Cancer Treatment
New method may offer safer alternative to target tumors and minimize awful side effects for cancer patients.
Prehistoric Molecular Code Offers New Insight on Cancer Cell Migration
Researchers find mechanism that enables cells to migrate in a specific tissue.
Is the United States Spending Enough on Global Health Care?
Partisan split found in those who believe America should devote more funds to global health care initiatives.
Mathematical Formula May Help Predict Cancer Progression
Researchers find cancer evolves in specific patterns that are predictable through the laws of nature.
Harnessing Tumor Suppressor Gene May Enhance Cancer Treatment
Genetic modifications enhance local DNA repair and protection in cancer treatment.
Experimental Stem Cell Treatment Shows Promise Halting ALS
Some patients with amyotrophic lateral sclerosis who received the stem cell therapy showed less progression and improved respiratory and motor functions.
CMS Announces Expansion of Medicare Accountable Care Organization Intiative
ACOs combined for a total net savings of $411 million in 2014.
New Treatment Model Could Improve Ovarian Cancer Survival
Aggressive surgery to remove all cancer cells followed by targeted chemotherapy shows potential to significantly improve ovarian cancer survival.
Beyond the Ice Bucket Challenge: Patients Fight for New ALS Therapies
A young Navy veteran finds hope in his struggle with amyotrophic lateral sclerosis, as the hunt for a cure continues.
FDA Grants Chronic Lymphocytic Leukemia Drug Priority Review
Venetoclax is a B-cell lymphoma-2 protein inhibitor for the treatment of CLL patients who received a least one prior therapy.
PARP Inhibitor Combination Therapy Could Enhance Cancer Treatment
Tumors that over-express a specific oncogene may benefit from combination therapy regardless of cancer type.